Switch theme
Sign up to access all valuation multiples
Eurobio Scientific is one of the leading providers of specialty in vitro diagnostics and life-science solutions. The product portfolio includes Tetanos Quick Stick, BJI InoPlex, AlloMap, and TEDAC Consortium.
2018
127
LTM Revenue $161M
LTM EBITDA $32.6M
$294M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Eurobio Scientific has a last 12-month revenue (LTM) of $161M and a last 12-month EBITDA of $32.6M.
In the most recent fiscal year, Eurobio Scientific achieved revenue of $174M and an EBITDA of $30.8M.
Eurobio Scientific expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Eurobio Scientific valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $161M | XXX | $174M | XXX | XXX | XXX |
| Gross Profit | $161M | XXX | $80.8M | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | 46% | XXX | XXX | XXX |
| EBITDA | $32.6M | XXX | $30.8M | XXX | XXX | XXX |
| EBITDA Margin | 20% | XXX | 18% | XXX | XXX | XXX |
| EBIT | $28.2M | XXX | $11.0M | XXX | XXX | XXX |
| EBIT Margin | 18% | XXX | 6% | XXX | XXX | XXX |
| Net Profit | $11.5M | XXX | $4.5M | XXX | XXX | XXX |
| Net Margin | 7% | XXX | 3% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $6.8M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Eurobio Scientific's stock price is EUR 25 (or $28).
Eurobio Scientific has current market cap of EUR 251M (or $282M), and EV of EUR 262M (or $294M).
See Eurobio Scientific trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $294M | $282M | XXX | XXX | XXX | XXX | $1.12 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Eurobio Scientific has market cap of $282M and EV of $294M.
Eurobio Scientific's trades at 1.7x EV/Revenue multiple, and 9.5x EV/EBITDA.
Equity research analysts estimate Eurobio Scientific's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Eurobio Scientific has a P/E ratio of 24.6x.
See valuation multiples for Eurobio Scientific and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $282M | XXX | $282M | XXX | XXX | XXX |
| EV (current) | $294M | XXX | $294M | XXX | XXX | XXX |
| EV/Revenue | 1.8x | XXX | 1.7x | XXX | XXX | XXX |
| EV/EBITDA | 9.0x | XXX | 9.5x | XXX | XXX | XXX |
| EV/EBIT | 10.4x | XXX | 26.7x | XXX | XXX | XXX |
| EV/Gross Profit | 1.8x | XXX | n/a | XXX | XXX | XXX |
| P/E | 24.6x | XXX | 62.7x | XXX | XXX | XXX |
| EV/FCF | 13.9x | XXX | 19.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialEurobio Scientific's last 12 month revenue growth is 9%
Eurobio Scientific's revenue per employee in the last FY averaged $1.4M, while opex per employee averaged $0.5M for the same period.
Eurobio Scientific's rule of 40 is 29% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Eurobio Scientific's rule of X is 43% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Eurobio Scientific and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 9% | XXX | 3% | XXX | XXX | XXX |
| EBITDA Margin | 20% | XXX | 18% | XXX | XXX | XXX |
| EBITDA Growth | 17% | XXX | 11% | XXX | XXX | XXX |
| Rule of 40 | 29% | XXX | 27% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 43% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $1.4M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.5M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 19% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 3% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 40% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Australian Clinical Labs | XXX | XXX | XXX | XXX | XXX | XXX |
| Healius | XXX | XXX | XXX | XXX | XXX | XXX |
| Integral Diagnostics | XXX | XXX | XXX | XXX | XXX | XXX |
| Sonic Healthcare | XXX | XXX | XXX | XXX | XXX | XXX |
| Bangkok Dusit Medical Services | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Eurobio Scientific acquired XXX companies to date.
Last acquisition by Eurobio Scientific was XXXXXXXX, XXXXX XXXXX XXXXXX . Eurobio Scientific acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Eurobio Scientific founded? | Eurobio Scientific was founded in 2018. |
| Where is Eurobio Scientific headquartered? | Eurobio Scientific is headquartered in France. |
| How many employees does Eurobio Scientific have? | As of today, Eurobio Scientific has 127 employees. |
| Who is the CEO of Eurobio Scientific? | Eurobio Scientific's CEO is Mr. Jean-Michel Carle Grandmougin. |
| Is Eurobio Scientific publicy listed? | Yes, Eurobio Scientific is a public company listed on PAR. |
| What is the stock symbol of Eurobio Scientific? | Eurobio Scientific trades under ALERS ticker. |
| When did Eurobio Scientific go public? | Eurobio Scientific went public in 2005. |
| Who are competitors of Eurobio Scientific? | Similar companies to Eurobio Scientific include e.g. Australian Clinical Labs, Healius, Integral Diagnostics, Sonic Healthcare. |
| What is the current market cap of Eurobio Scientific? | Eurobio Scientific's current market cap is $282M |
| What is the current revenue of Eurobio Scientific? | Eurobio Scientific's last 12 months revenue is $161M. |
| What is the current revenue growth of Eurobio Scientific? | Eurobio Scientific revenue growth (NTM/LTM) is 9%. |
| What is the current EV/Revenue multiple of Eurobio Scientific? | Current revenue multiple of Eurobio Scientific is 1.8x. |
| Is Eurobio Scientific profitable? | Yes, Eurobio Scientific is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Eurobio Scientific? | Eurobio Scientific's last 12 months EBITDA is $32.6M. |
| What is Eurobio Scientific's EBITDA margin? | Eurobio Scientific's last 12 months EBITDA margin is 20%. |
| What is the current EV/EBITDA multiple of Eurobio Scientific? | Current EBITDA multiple of Eurobio Scientific is 9.0x. |
| What is the current FCF of Eurobio Scientific? | Eurobio Scientific's last 12 months FCF is $21.1M. |
| What is Eurobio Scientific's FCF margin? | Eurobio Scientific's last 12 months FCF margin is 13%. |
| What is the current EV/FCF multiple of Eurobio Scientific? | Current FCF multiple of Eurobio Scientific is 13.9x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
